Skip to content
You are not logged in |Login  

LEADER 00000cam a2200649M  4500 
001    ocn972010894 
003    OCoLC 
005    20180211085734.6 
006    m     o  d         
007    cr unu|||||||| 
008    160322nuuuuuuuuxx      o     000 0 eng d 
019    828140652|a923653298|a972077327|a1009010894 
020    9781619423206|q(electronic book) 
020    1619423200|q(electronic book) 
020    9781619423169|q(electronic book) 
020    1619423162|q(electronic book) 
035    (OCoLC)972010894|z(OCoLC)828140652|z(OCoLC)923653298
       |z(OCoLC)972077327|z(OCoLC)1009010894 
040    LVT|beng|epn|cLVT|dOCLCQ|dYDX|dYDXCP|dN$T|dE7B|dEBLCP
       |dDEBSZ|dD6H|dAGLDB|dN$T|dOCLCO 
049    RIDW 
050  4 RC889|b.E74 2012 
072  7 HEA|x045000|2bisacsh 
082 04 616.6922|223 
090    RC889|b.E74 2012 
100 1  Grant, Paul Steven.|0https://id.loc.gov/authorities/names/
       n2013015851 
245 10 Erectile Dysfunction: Causes, Risk Factors and Management 
       (Human Sexuality). 
264  1 |bNova Science Publishers Incorporated. 
300    1 online resource 
336    text|btxt|2rdacontent 
337    computer|bc|2rdamedia 
338    online resource|bcr|2rdacarrier 
347    text file|2rdaft 
504    Includes bibliographical references and index. 
505 0  ""ERECTILE DYSFUNCTION ""; ""ERECTILE DYSFUNCTION ""; 
       ""Contents ""; ""Foreword""; ""Part One ""; 
       ""Introduction""; ""References ""; ""A Primary Care 
       Approach to Erectile Dysfunction ""; ""Abstract ""; 
       ""Introduction ""; ""Assessment of ED ""; ""Common Causes 
       of Erectile Dysfunction ""; ""Baseline Investigations ""; 
       ""Men in the Following Categories Require Referral ""; 
       ""Developing a Treatment Plan ""; ""Phase 1: Stabilise 
       General Clinical Condition ""; ""Phase 2: Treat 
       Correctable Causes ""; ""Phase 3: Initiate Specific 
       Therapy for Erectile Dysfunction ""; ""Phase 4: Onward 
       Referral "" 
505 8  ""Conclusion """"References ""; ""Erectile Dysfunction: 
       Causes, Risk Factors and Management ""; ""Abstract ""; 
       ""Introduction ""; ""Epidemiology ""; ""Physiology of 
       Erection ""; ""Pathophysiology of Erectile Dysfunction "";
       ""Psychogenic ED ""; ""Neurogenic ED ""; ""Hormonal Causes
       of ED ""; ""Vascular Causes of ED ""; ""Drug-Induced 
       Erectile Dysfunction ""; ""Erectile Dysfunction due to 
       other Systemic Diseases and Ageing ""; ""Renal Disease "";
       ""Spinal Cord Injury ""; ""Correlations of ED with CAD and
       DM ""; ""Correlation of ED with Lower Urinary Tract 
       Symptoms (LUTS) "" 
505 8  ""Clinical Evaluation """"Quantification of the Severity 
       of Erectile Dysfunction and Improvement ""; ""Physical 
       Examination ""; ""Laboratory Studies ""; ""Special Studies
       ""; ""Penile Duplex Doppler Imaging ""; ""Management of 
       Erectile Dysfunction ""; ""I. Medical and other Non-
       surgical Treatment ""; ""Phosphodiesterase Type 5 
       Inhibitors (PDE5 Inhibitors) ""; ""1. Sildenafil Citrate 
       (Viagra) ""; ""2. Vardenafil (Levitra) ""; ""3. Tadalafil 
       (Cialis) ""; ""4. Use of PDE5 Inhibitors and 
       Cardiovascular Safety ""; ""Apomorphine (Uprima) ""; 
       ""Adrenergic-Receptor Antagonists "" 
505 8  ""1. Phentolamine (Regitine) """"2. Yohimbine ""; 
       ""Trazodone (Desyrel, Mesyrel) ""; ""Dietary Supplements 
       and Erectile Dysfunction ""; ""1. Ginkgo Bilboa ""; ""2. L
       -Arginine ""; ""Intracavernosal and Intraurethral Therapy 
       ""; ""1. Alprostadil (Prostaglandin E1, Caverject, 
       Medicated Urethral System for Erection) ""; ""2. 
       Papaverine ""; ""3. Phentolamine (Regitine) ""; ""4. 
       Moxisylyte Chlorohydrate ""; ""5. Chlorpromazine 
       (Thorazine) ""; ""6. Vasoactive Intestinal Polypeptide 
       (VIP) ""; ""Testosterone ""; ""Vacuum Constrictive Device 
       ""; ""II. Surgical Treatment "" 
505 8  ""Penile Prostheses Implantation """"Penile 
       Revascularization ""; ""Venectomy ""; ""III. Future 
       Treatments ""; ""Gene Therapy ""; ""1. Gene Therapy and 
       NOS ""; ""2. Gene Therapy and the Human Calcium-Sensitive 
       Potassium Channel Subtype ""; ""3. Gene Therapy and 
       Vascular Endothelial Growth Factor (VEGF) and other 
       Molecular Targets""; ""Conclusion""; ""References ""; 
       ""Current and Emerging Novel Diagnostic Tools for the 
       Diagnosis of Male Erectile Dysfunction ""; ""Abstract ""; 
       ""Introduction ""; ""Consensus and Major International 
       Guidelines on the Investigations of ED "" 
590    eBooks on EBSCOhost|bEBSCO eBook Subscription Academic 
       Collection - North America 
650  0 Impotence.|0https://id.loc.gov/authorities/subjects/
       sh85064658 
650  0 Impotence|0https://id.loc.gov/authorities/subjects/
       sh85064658|xEtiology.|0https://id.loc.gov/authorities/
       subjects/sh00005666 
650  0 Impotence|0https://id.loc.gov/authorities/subjects/
       sh85064658|xTreatment.|0https://id.loc.gov/authorities/
       subjects/sh99005040 
650  7 Impotence.|2fast|0https://id.worldcat.org/fast/968233 
650  7 Diseases|xCauses and theories of causation.|2fast|0https:/
       /id.worldcat.org/fast/895163 
650  7 Impotence|xTreatment.|2fast|0https://id.worldcat.org/fast/
       968241 
650  7 Erectile dysfunction.|2homoit|0https://homosaurus.org/v3/
       homoit0000398 
655  4 Electronic books. 
776 08 |cOriginal|z9781619423169|z1619423162|w(OCoLC)779245509 
830  0 Online access: EBSCO eBook Clinical Collection (EBSCOhost)
856 40 |uhttps://rider.idm.oclc.org/login?url=http://
       search.ebscohost.com/login.aspx?direct=true&scope=site&
       db=nlebk&AN=540911|zOnline eBook. Access restricted to 
       current Rider University students, faculty, and staff. 
856 42 |3Instructions for reading/downloading the EBSCO version 
       of this eBook|uhttp://guides.rider.edu/ebooks/ebsco 
901    MARCIVE 20231220 
948    |d20180214|cEBSCO|tebscoebooksacademic MERGES 2-10-18 
       |lridw 
948    |d20171117|cEBSCO|tebscoebooksacademic MERGE|lridw 
948    |d20160607|cEBSCO|tebscoebooksacademic|lridw 
994    92|bRID